Literature DB >> 8173018

A comparison of propofol and methohexital as anesthetic agents for ECT: effects on seizure duration, therapeutic outcome, and memory.

B Mårtensson1, A Bartfai, B Hallén, C Hellström, T Junthé, M Olander.   

Abstract

The effects of the anesthetic agents propofol and methohexital on seizure duration, clinical outcome, recovery, and memory in electroconvulsive therapy (ECT) were studied in a double-blind trial. The study comprised 53 patients, 47 patients with major depression and six patients with other diagnoses according to DSM-III. Several recent clinical studies with a crossover design have shown a reduced seizure duration for anesthesia with propofol in comparison with both methohexital and thiopental. Propofol significantly reduced the seizure duration in this study without reducing the therapeutic outcome as measured by the Montgomery-Asberg Depression Rating Scale. Propofol did not significantly alter the length of the course of ECT; however, a slightly prolonged course for women cannot be completely ruled out. There were no significant differences between the two agents in effects on recovery times after anesthesia and on anterograde memory. In general, it seems that propofol is as effective as methohexital as an induction agent for ECT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173018     DOI: 10.1016/0006-3223(94)91150-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

1.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

2.  Management of poor postictal suppression during electroconvulsive therapy with propofol anesthesia: a report of two cases.

Authors:  Jonathan T Stewart
Journal:  J Anesth       Date:  2012-07-24       Impact factor: 2.078

3.  Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study.

Authors:  Carolin Hoyer; Laura Kranaster; Christoph Janke; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

4.  The Combination of Propofol and Ketamine Does Not Enhance Clinical Responses to Electroconvulsive Therapy in Major Depression-The Results From the KEOpS Study.

Authors:  Jerome Brunelin; Sylvain Iceta; Marion Plaze; Raphaël Gaillard; Louis Simon; Marie-Françoise Suaud-Chagny; Filipe Galvao; Emmanuel Poulet
Journal:  Front Pharmacol       Date:  2020-09-15       Impact factor: 5.810

Review 5.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

6.  Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT.

Authors:  Chittaranjan Andrade; Shivashanmugam Thyagarajan; Nagendra Madan Singh; Pabbisetty S Vinod; N Sanjay Kumar Rao; J Suresh Chandra
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

Review 7.  Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression.

Authors:  Peng Lihua; Min Su; Wei Ke; Patrick Ziemann-Gimmel
Journal:  Cochrane Database Syst Rev       Date:  2014-04-11

Review 8.  A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression.

Authors:  Guillaume Fond; Djamila Bennabi; Emmanuel Haffen; Lore Brunel; Jean-Arthur Micoulaud-Franchi; Anderson Loundou; Christophe Lançon; Pierre-Michel Llorca; Pascal Auquier; Laurent Boyer
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.